PEDIATRIC HEMATOLOGY-ONCOLOGY PROGRAM OVERVIEW

Our specialized teams treat newborns, children, teenagers, and young adults with all types of cancer, immunologic deficiencies, and blood disorders including, but not limited to:

- Leukemia
- Lymphomas
- Tumors of the Brain and Central Nervous System
- Neuroblastoma
- Sarcomas
 - Osteosarcoma
 - Rhabdomyosarcoma
 - Ewing Sarcoma
 - Desmoplastic Small Round Cell Tumor
- Retinoblastoma
- Wilms' Tumor
- · Bone Marrow Failure
- Immunodeficiency Syndrome
- Other Rare Cancers and Blood Disorders

Our dedicated pediatric facilities include a comprehensive ambulatory care center and specialized inpatient and intensive care units.

Visit us at: www.mskcc.org/pediatrics

REFER A PATIENT

Contact our Pediatric Program directly on

212-639-5954

Patients can be see within 24 hours. MSK has insurance contracts with most major health plans in the New York tristate area.

Our Team Leaders

Andrew Kung, MD, PhD Chair, Department of Pediatrics

Paul A. Meyers, MD Vice Chair, Academic Affairs, Department of Pediatrics

Farid Boulad, MD Medical Director, Pediatric Ambulatory Care Center

James S. Killinger, MD Medical Director, Pediatric Intensive Care Unit

David H. Abramson, MD Chief, Ophthalmic Oncology Service

Nai-Kong V. Cheung, MD, PhD Head, Neuroblastoma Program

John H. Healey, MD, FACS Chief, Orthopaedic Service

Matthias A. Karajannis, MD, MS Chief, Pediatric Neuro-Oncology Program

Michael P. La Quaglia, MD, FACS, FRCS Chief, Pediatric Surgical Service

Richard J. O'Reilly, MD Chief, Pediatric Marrow Transplant Service

Charles A. Sklar, MD Director, Long-Term Follow-Up Program

Peter G. Steinherz, MD Director, Leukemia and Lymphoma Studies

Sign up for OncoNotes, MSK's clinical updates newsletter.

Go to mskcc.org, click on the $\bf For\ Health\ Professionals$ section, and choose "Sign up for our e-newsletter."

You can also arrange for a physician liaison to visit your practice by emailing **physicianrelations@mskcc.org**.





Pediatric Hematology-Oncology Program



WHY CHOOSE MSK FOR PEDIATRIC AND YOUNG ADULT CANCER CARE?

Expertise

- We care for over 150 patients a day, seeing more children, teens, and young adults with cancer daily than any other hospital in the nation.
- Our medical and radiation oncologists, transplant specialists, and surgeons are highly specialized, world leaders in pediatric oncology.
- MSK research has led to the development of many treatments that are now the standard of care in childhood cancer.

By the Numbers

100+ years of pediatric hematology-oncology experience

physicians, nurses, and other specialists dedicated solely to the care of children with cancer

850+ new pediatric patients seen annually

90% of treatments provided on an outpatient basis 100+ clinical trials with new options continually developing



Patient-Centered Care

At MSK, a wide range of resources is available to meet the individual needs of our patients and families.

Child Psychiatry and Counseling: For patients and family members at the bedside or in private settings.

Pain Management: Pain and palliative specialists using innovative techniques and new medications.

School Program: Run by full-time teachers for pre kindergarten through grade 12.

Complementary Therapies: Non-pharmacological interventions, including yoga and music therapy, provided by specialists.

Child Life Therapists: Use strategies to help adjust to treatment requirements and the hospital setting.

Teen and Young Adult Program (TYA@MSK): Recognizes the unique needs of this population and provides age-appropriate services.

Precision Cancer Medicine

Individualized Approach

Our unparalleled diagnostic capabilities allow us to pinpoint the precise molecular causes of disease, and choose from a broad spectrum of standard and innovative therapies to maximize efficacy and decrease the toxicities of treatment.

State-of-the-art Diagnosis

- We routinely sequence tumor DNA to identify changes in cancer-causing genes, and have sequenced over 20,000 patients, the most of any cancer hospital in the world.
- We monitor treatment efficacy using state-of-the-art technologies, including liquid biopsies and innovative imaging technologies.
- We are the only COG-certified flow cytometry center in the northeast for the assessment of leukemia.

State-of-the-art Medicine

- Immunotherapies for neuroblastoma, sarcomas, brain tumors, and central nervous system diseases.
- Vision-sparing intra-arterial therapy for retinoblastoma, saving eyes and reaching survival rates of nearly 99 percent.
- Bone marrow and stem cell transplants, including for children without a sibling donor.
- Cell therapies for the treatment of disease and viral infections.
- Advanced radiotherapy to minimize toxic effects on normal tissues.